Prothena Corporation

Prothena Corporation PP&E per Employee

The PP&E per Employee of Prothena Corporation (PRTA) as of Oct 15, 2026 is 119,522.39 USD. In the previous year, PP&E per Employee was 30,029.85 USD — a change of 298.01% (higher).

PP&E per Employee

119,522.39USD

YoY

298.01%

Last updated:

PP&E per Employee of Prothena Corporation is 2022 119,522.39 USD. PP&E per Employee of Prothena Corporation was 2021 30,029.85 USD. It decreases by 298.01% higher compared to the previous year.

The Prothena Corporation PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
57,641.79 USD
Jan 1, 2016
842,567.16 USD
Jan 1, 2017
820,746.27 USD
Jan 1, 2018
788,582.09 USD
Jan 1, 2019
57,820.90 USD
Jan 1, 2020
38,074.63 USD
Jan 1, 2021
30,029.85 USD
Jan 1, 2022
119,522.39 USD
The Prothena Corporation PP&E per Employee history
YEARPP&E per EmployeeYoY
119,522.39USD+298.01%
30,029.85USD-21.13%
38,074.63USD-34.15%
57,820.90USD-92.67%
788,582.09USD-3.92%
820,746.27USD-2.59%
842,567.16USD+1,361.73%
57,641.79USD+23.74%
46,582.09USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prothena Corporation stock

PP&E per Employee of Prothena Corporation is 119,522.39 USD in 2022.

PP&E per Employee of Prothena Corporation changed from 30,029.85 USD to 119,522.39 USD, representing a 298.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Prothena Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Prothena Corporation

All Key Metrics — Prothena Corporation